Kynam Capital Management’s ACELYRIN SLRN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-847,366
Closed -$2.66M 34
2024
Q4
$2.66M Hold
847,366
0.16% 29
2024
Q3
$4.18M Buy
847,366
+16,056
+2% +$82.9K 0.32% 24
2024
Q2
$3.67M Buy
831,310
+434,931
+110% +$2.04M 0.28% 24
2024
Q1
$2.68M Sell
396,379
-803,621
-67% -$6.1M 0.28% 22
2023
Q4
$8.95M Hold
1,200,000
0.99% 19
2023
Q3
$12.2M Buy
+1,200,000
New +$25.5M 2% 12

Other funds holding SLRN

Kynam Capital Management's SLRN Position: Q1 2025 in Review

Kynam Capital Management sold out of ACELYRIN (SLRN) in Q1 2025, closing a stake of 847,366 shares — an estimated $2.66M sold.

Kynam Capital Management first reported a position in SLRN in Q3 2023 and held it in 6 quarters. The position peaked at $12.2M in Q3 2023. 105 funds tracked by Wall St. Rank hold SLRN as of Q1 2025.

  • Kynam Capital Management reported no remaining ACELYRIN position as of Q1 2025 after selling out during the quarter.
  • Kynam Capital Management sold 847,366 ACELYRIN shares in Q1 2025, an estimated $2.66M.
  • Kynam Capital Management first reported a position in ACELYRIN in Q3 2023 and held it in 6 quarters.
  • Kynam Capital Management's ACELYRIN position peaked at $12.2M in Q3 2023.
  • 105 funds tracked by Wall St. Rank held ACELYRIN as of Q1 2025.

Based on Kynam Capital Management's 13F filing for Q1 2025, filed 15 May 2025.